DeCure for Generalized dominant dystrophic epidermolysis bullosa
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for generalized dominant dystrophic epidermolysis bullosa — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGeneralized dominant dystrophic epidermolysis bullosa maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for generalized dominant dystrophic epidermolysis bullosa is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 2006 study analysed 332 families with dystrophic epidermolysis bullosa (DEB) and identified 355 mutant alleles out of an anticipated 438 (81.1%), comprising 242 distinct mutations, 138 of which were novel. All mutations were found in the COL7A1 gene, encoding type VII collagen, and no evidence of mutations in any other gene was obtained. The authors reported that phenotype–genotype correlations contributed to improved subclassification of DEB with prognostic implications, and that the mutation information formed the basis for accurate genetic counselling and prenatal diagnosis.
A 2010 case report described a neonate with autosomal dominant bullous dermolysis of the newborn, a rare subtype of dystrophic epidermolysis bullosa, carrying a heterozygous missense mutation p.G1673R in COL7A1. Fewer than 30 cases of this subtype had been reported, and the authors noted that the pathogenesis was poorly understood, with only a minority of cases having had pathogenic mutations identified. The same mutation had previously been reported as one mutant allele in a case of recessive dystrophic epidermolysis bullosa (generalised other).
A 2009 review stated that patients with recessive dystrophic epidermolysis bullosa develop numerous life-threatening skin cancers, but the reasons remained unclear. The authors summarised observational and experimental data and discussed proposed theories for the development of such aggressive skin cancers, concluding that a context-driven situation seemed to be emerging but that more focused research was required to elucidate the pathogenesis of epidermolysis bullosa-associated squamous cell carcinoma.
What is still missing is a clear molecular mechanism linking COL7A1 mutations to cancer development, prospective data on cancer incidence and progression in defined genotype groups, and any clinical trial testing a specific intervention to prevent or treat squamous cell carcinoma in this population. No drug, repurposed or otherwise, was mentioned in any of these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 2006 · 280 citations · open access
Epidermolysis bullosa. II. Type VII collagen mutations and phenotype–genotype correlations in the dystrophic subtypes
AbstractBACKGROUND: The dystrophic forms of epidermolysis bullosa (DEB), a group of heritable blistering disorders, show considerable phenotypic variability, and both autosomal dominant and autosomal recessive inheritance can be recognised. DEB is derived from mutations in the type VII collagen gene (COL7A1), encoding a large collagenous protein that is the predominant, if not exclusive, component of the anchoring fibrils at the dermal-epidermal junction. METHODS: The Dystrophic Epidermolysis Bullosa Research Association Molecular Diagnostics Laboratory (Philadelphia, Pennsylvania, USA), established in 1996, has analysed more than 1000 families with different forms of epidermolysis bullosa, among them 332 families with DEB. DNA specimens were subjected to mutation analysis by polymerase chain reaction (PCR) amplification of all 118 exons and flanking intronic sequences of COL7A1, followed either by heteroduplex scanning and sequencing of the PCR products demonstrating heteroduplexes or by direct nucleotide sequencing. RESULTS: 355 mutant alleles out of the anticipated 438 (81.1%) were disclosed. Among these mutations, a total of 242 mutations were distinct and 138 were novel, previously unreported mutations. No evidence of mutations in any other gene was obtained. DISCUSSION: Examination of the mutation database suggested phenotype-genotype correlations, contributing to the improved subclassification of DEB with prognostic implications. The mutation information also forms the basis for accurate genetic counselling and prenatal diagnosis in families at risk for recurrence.
Australasian Journal of Dermatology · 2010 · 8 citations
Autosomal dominant bullous dermolysis of the newborn associated with a heterozygous missense mutation p.G1673R in type VII collagen
AbstractBullous dermolysis of the newborn is an inherited mechano-bullous disorder classed as a rare subtype of dystrophic epidermolysis bullosa. Fewer than 30 cases of bullous dermolysis of the newborn have been reported in the literature and the pathogenesis of the disease is poorly understood. Only a minority of cases have had pathogenic mutations identified. We present a case of a neonate born to non-consanguineous Caucasian parents with an exon 54 (c.5017G > A, p.G1673R) mutation reported as one mutant allele in a case of recessive dystrophic epidermolysis bullosa (generalized other).
AbstractPatients with recessive dystrophic epidermolysis bullosa develop numerous life-threatening skin cancers. The reasons for this remain unclear. Parallels exist with other scarring skin conditions, such as Marjolin ulcer. We summarize observational and experimental data and discuss proposed theories for the development of such aggressive skin cancers. A context-driven situation seems to be emerging, but more focused research is required to elucidate the pathogenesis of epidermolysis bullosa-associated squamous cell carcinoma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
